The Clinical Rationale for Integrating Oral Semaglutide into Your Practice

As a Medical Director, I am often asked by clinic owners if they should pivot toward offering oral GLP-1 options. With the 2026 landscape of weight management becoming increasingly competitive, diversifying your delivery methods is a savvy move, but it requires a nuanced clinical approach to manage both patient health and business risk.

Oral semaglutide offers a non-invasive alternative that appeals to a broader demographic, including patients seeking non-injectable GLP-1 options. From a compliance and safety standpoint, here is what you need to know:

• Efficacy vs. adherence: While clinical trials show parity with injectables (~15% weight loss), real-world "typical use" often sees a dip in efficacy. This is largely due to the strict 30-minute fasting requirement. If a patient isn't seeing the results they expected, they may become frustrated.
• Side effect management: The GI profile is comparable across both mediums. However, daily oral dosing can lead to a more stable steady-state concentration, which some patients prefer over the "peak and trough" of a weekly injection.

Managing Patient Expectations and Business Risk

One critical consideration for Med Spa owners is patient satisfaction. Because the oral pill is more "user-dependent" than the injection, there is a higher chance of varied results in a structured weight loss program.

• The refund risk: If a patient is paying a premium for a program and doesn't see the scale move because they had their coffee 10 minutes after their pill, they may blame the product. This can lead to increased complaints and requests for refunds.
• The solution: Success in an oral program requires robust adherence coaching. Your staff must be trained to educate and emphasize how to maximize the benefits of the oral medication while protecting outcomes and reputation.

Operational Advantages of Offering Oral Semaglutide

1. Logistics: Oral medications do not require the "cold chain" refrigeration necessary for injectable pens, simplifying shipping and storage.
2. Patient acquisition: You can capture the "needle-averse" segment of the market that has stayed on the sidelines of injectable therapy.
3. Maintenance phase: The oral version may be a good tool for long-term weight maintenance and "food noise" suppression after a patient reaches their goal on injectables.

The Current Landscape: No FDA-Approved Oral Tirzepatide

As clinics explore oral expansion, it’s important to distinguish between FDA-approved options and emerging compounded alternatives.

Unlike semaglutide, which has an FDA-approved oral version, there is currently no FDA-approved oral form of tirzepatide. While pharmaceutical companies are working on oral "small molecule" alternatives (like orforglipron) that target similar pathways, a formal "tirzepatide pill" has not yet cleared the rigorous clinical trial process required for federal approval.

The Role of Compounded Oral Tirzepatide

Because of the massive demand and ongoing supply chain shifts, some compounding pharmacies have begun offering compounded oral tirzepatide (often as sublingual "Rapid Dissolve Tablets" or RDTs).

As a board-certified physician, here is my professional perspective on these options:

• The theoretical potential: In theory, delivering the same "dual-agonist" load (targeting both GLP-1 and GIP receptors) orally should produce significant metabolic benefits. It is reasonable to assume that, similar to semaglutide, an oral version might be slightly less effective than the injection due to absorption hurdles, but could still offer a very comparable side effect and results profile for the right patient.

• The lack of data: It is important to be transparent: We do not yet have large-scale, peer-reviewed studies on the effectiveness of oral compounded tirzepatide. We are operating on clinical theory and personalized observation rather than the robust data we have for semaglutide.

• A personalized approach: Utilizing a compounded oral medication in the absence of an FDA-approved version is not necessarily "irresponsible." In many cases, it is a legitimate part of a personalized, physician-led weight management plan—especially for patients who cannot tolerate injections or have specific medical needs that branded products don't meet.

The Physician’s Verdict

I believe the oral semaglutide option is a great, evidence-based tool that can perform nearly as well as the injection for the right patient. However, from a risk management perspective, I recommend clear informed consent that explains the potential for slightly lower effectiveness compared to the injection if the protocol is not followed perfectly.

If you are considering oral tirzepatide from a compounding pharmacy, it should be done under the strict supervision of a qualified medical provider. We must use our best clinical judgment to weigh the theoretical benefits against the current lack of standardized evidence.

For some patients, this customized approach is the key to their success; for others, sticking to the injectable or the FDA-approved oral semaglutide is the safer bet.

‍

by Dr. Alex Saucedo, Medical Director at Arora Health

Dr. Alex Saucedo is a Dual Board-Certified Physician and dynamic healthcare leader with over eight years of experience bridging clinical excellence and modern, scalable healthcare delivery. His broad expertise spans pediatrics, acute care, mental health, wellness, and obesity medicine — serving patients of all ages through both in-person and telehealth models.

Having practiced across traditional clinics, hospital systems, and innovative telehealth platforms, he brings a collaborative, evidence-based approach to clinical oversight.